Pioneers of the world’s first TCR therapy

Jan. 10, 2025 • Time: 7:00 AM EST

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan. 6, 2025 • Time: 7:00 AM EST

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan. 2, 2025 • Time: 7:00 AM EST

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Dec. 23, 2024 • Time: 7:00 AM EST

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Dec. 17, 2024 • Time: 7:00 AM EST

Immunocore announces dosing of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

Dec. 11, 2024 • Time: 7:00 AM EST

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

Dec. 3, 2024 • Time: 1:00 AM EST

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Nov. 8, 2024 • Time: 7:00 AM EST

Immunocore to present at upcoming investor conferences

Nov. 6, 2024 • Time: 7:00 AM EST

Immunocore reports third quarter financial results and provides a business update

Sep. 14, 2024 • Time: 3:00 AM EDT

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer